New corporate identity aligns the public company with its battery technology platform and commercialization strategy

PORT JEFFERSON, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — Innovative Holdings Alliance, Inc. (formerly OTC: IHAI) today announced that it has changed its corporate name to Premergy, Inc. The Company’s common stock is expected to begin trading under the new ticker symbol PMGY effective with the market open on November 12, 2026. The Company’s CUSIP number remains unchanged. The name and symbol changes are intended to align the Company’s public identity with its Premergy technology platform, operating focus and long-term commercialization strategy.

About Premergy, Inc.
Premergy is an advanced energy technology company developing intelligent battery architecture and power-management technologies. Its platform is designed to manage how battery cells and systems are configured and controlled during charging, discharging and energy recovery. Rather than manufacturing battery cells, Premergy focuses on the control architecture and intellectual property intended to help battery-powered systems operate more efficiently and flexibly. ⁠

The Company is pursuing opportunities to develop and commercialize its technology through licensing, strategic partnerships and other collaborations. Potential applications include electric vehicles, drone and unmanned aerial systems, data-center infrastructure and energy storage. Premergy continues to advance engineering and validation work as it evaluates these markets and potential uses for its intellectual property. The Company is also working with Sigma Law Group LLC to evaluate potential monetization and enforcement opportunities for its electric-vehicle patent portfolio. ⁠

For more information, visit www.premergy.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, among others, statements regarding the expected timing and implementation of the Company’s trading symbol change; the development, performance and potential applications of its technology; and its validation, licensing, partnership and commercialization plans.

Forward-looking statements are based on current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These include, among others, risks related to corporate-action processing and timing; the Company’s ability to obtain financing, develop and validate its technology, protect and commercialize its intellectual property, establish strategic relationships, achieve market acceptance, and comply with applicable regulatory and market requirements. Forward-looking statements are not guarantees of future performance. Except as required by law, the Company undertakes no obligation to update them.

Investor Relations and Media Contact

Leonard Braumberger
Welston Group Inc.
IR@premergy.com ⁠⁠

Core Pawn Drives Record Fourth Quarter

AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) — EZCORP, Inc. (NASDAQ: EZPW), a leading provider of pawn transactions in the United States, Latin America and the Caribbean, today announced results for its fourth quarter and full year ended September 30, 2026.

Unless otherwise noted, all amounts in this release are in conformity with U.S. generally accepted accounting principles (“GAAP”) and comparisons shown are to the same period in the prior year.

FOURTH QUARTER HIGHLIGHTS

  • Net income attributable to EZCORP increased 28% to $34.3 million. On an adjusted basis1, net income attributable to EZCORP increased 27% to $34.1 million.
  • Diluted earnings per share (EPS) increased 26% to $0.43. On an adjusted basis1, diluted earnings per share increased 23% to $0.43.
  • Adjusted EBITDA increased 33% to $64.0 million.
  • Total revenues increased 33% to $447.1 million, while gross profit increased 29% to $255.8 million.
  • Core pawn revenue increased 27% to $383.4 million and core pawn gross profit increased 29% to $243.6 million.
  • Pawn loans outstanding (PLO) increased 31% to $402.8 million.
  • We acquired the remaining interest in SMG in July 2026.
  • We grew our footprint by 41 stores, comprised of 25 de novo stores, 22 acquired stores, the consolidation of 4 stores and the closure of 2 stores.

FULL YEAR 2026 HIGHLIGHTS

  • Net income attributable to EZCORP increased 51% to $165.9 million, an increase of $56.3 million. On an adjusted basis1, net income attributable to EZCORP increased 49% to $161.7 million.
  • Diluted earnings per share increased 46% to $2.07. On an adjusted basis1, diluted earnings per share increased 43% to $2.02.
  • Adjusted EBITDA increased by 47% to $276.7 million.
  • Total revenues increased 33% to $1,694.7 million, while gross profit increased 32% to $985.0 million.
  • Core pawn revenue increased 24% to $1,453.2 million and core pawn gross profit increased 27% to $913.2 million.
  • Grew our footprint by 230 stores comprised of 190 acquired stores, 48 de novo stores, the consolidation of 6 stores and the closure of 2 stores.

CEO COMMENTARY AND OUTLOOK

Lachie Given, Chief Executive Officer, stated, “We finished Fiscal 2026 with an exceptional quarter, driven by strong growth in our core pawn operating metrics across all of our geographies. Fourth quarter same-store PLO increased 13% in the U.S. and 25% in Latin America. Robust lending and higher merchandise sales and margin drove substantial earnings growth in the quarter even as scrap margins normalize, reflecting the strength, durability and compelling growth profile of our core pawn business. The full year was one of the best in our history, with diluted EPS increasing 46% to $2.07, alongside record revenue and pawn loans outstanding. We are excited to carry this momentum into fiscal 2027, continuing to serve our customers with passion and respect, and to enhance value for our shareholders.

“We significantly expanded our reach during the year, adding a net 230 stores through acquisitions and de novo openings to bring our total footprint to 1,590 locations, across 15 countries. These additions strengthened our presence in attractive existing markets, including Texas, Florida, Mexico and Guatemala, while SMG added new markets for us across the Caribbean and Central America. With SMG now wholly owned, we are focused on integrating the stores onto our systems and enhancing its culture and operating disciplines to elevate financial performance, in what remains a very exciting opportunity for us.

“These results build on our five-year track record of exceptional execution and earnings growth, demonstrating the operating leverage inherent in our business as we continue to scale. As we look ahead, our priorities remain consistent: to strengthen the core pawn business, expand our footprint through de novo stores and disciplined acquisitions, and allocate capital prudently, supported by a strong, liquid balance sheet. I thank our almost 10,000 team members for bringing People, Pawn, Passion to life, for another exceptional quarter and year of financial performance, positioning us well for further growth and long-term shareholder value.”

CONSOLIDATED RESULTS

Three Months Ended September 30, As Reported   Adjusted1
in millions, except per share amounts   2026     2025     2026     2025
               
Total revenues $ 447.1   $ 336.8   $ 439.8   $ 336.8
Gross profit $ 255.8   $ 198.6   $ 251.7   $ 198.6
Income before income taxes $ 47.7   $ 36.3   $ 47.2   $ 37.0
Consolidated net income attributable to EZCORP $ 34.3   $ 26.7   $ 34.1   $ 26.9
Diluted earnings per share attributable to EZCORP $ 0.43   $ 0.34   $ 0.43   $ 0.35
EBITDA (non-GAAP measure) $ 64.6   $ 47.3   $ 64.0   $ 48.0

Twelve Months Ended September 30 As Reported   Adjusted1
in millions, except per share amounts   2026     2025     2026     2025
               
Total revenues $ 1,694.7   $ 1,274.3   $ 1,657.6   $ 1,274.3
Gross profit $ 985.0   $ 746.1   $ 964.3   $ 746.1
Income before income taxes $ 224.3   $ 146.8   $ 217.8   $ 147.0
Consolidated net income attributable to EZCORP $ 165.9   $ 109.6   $ 161.7   $ 108.5
Diluted earnings per share attributable to EZCORP $ 2.07   $ 1.42   $ 2.02   $ 1.41
EBITDA (non-GAAP measure) $ 284.0   $ 187.6   $ 276.7   $ 187.9
                       
  • PLO increased 31% to $402.8 million (16% on a same-store2 basis), primarily due to additional stores (including SMG) and higher average loan size on jewelry collateral.
  • Fourth quarter revenues increased 33% and gross profit increased 29%, reflecting improved pawn service charges (PSC), merchandise sales, and jewelry scrap sales. Excluding SMG, total revenues increased 20% and gross profit increased 18%. Full year total revenues increased 33% and gross profit increased 32%.
  • PSC increased 29% in the fourth quarter as a result of higher average PLO and additional stores. Full year PSC increased 26%.
  • Fourth quarter and full year merchandise sales gross margin increased to 37% from 35%, while aged general merchandise decreased 152 basis points (bps) to 1.4% of total general merchandise inventory.
  • Fourth quarter jewelry scrap sales increased 86% due to increase in gold price and jewelry purchases, and jewelry scrap sales gross margin decreased to 19% from 29% (as the gold price declined from third quarter levels, compared to a sharp increase during the prior year quarter). Full year jewelry scrap sales increased 144% due to the increase in gold price and jewelry purchases, and jewelry scrap sales gross margin increased to 30% from 27%.
  • Net inventory increased 44% (26% on a same-store basis) due to an increase in PLO, layaways and purchases. For the quarter, inventory turnover was down to 2.2x, from 2.3x and remained flat at 2.4x for the full year.
  • Store expenses increased 21% in the fourth quarter and 25% for the full year (4% and 10% on a same-store basis, respectively), primarily due to additional stores and labor costs, including minimum wage increases in Latin America.
  • General and administrative expenses increased 30% in the fourth quarter, primarily due to expenses associated with SMG. Full year expenses increased 26% mainly due to labor costs (including higher incentive compensation) and expenses associated with SMG.
  • Fourth quarter income before taxes increased to $47.7 million, up 31% from $36.3 million, and adjusted EBITDA increased 33% to $64.0 million. Full year income before taxes increased by 53% to $224.3 million from $146.8 million, and adjusted EBITDA increased 47% to $276.7 million.
  • Diluted earnings per share increased 26% to $0.43 for the fourth quarter. On an adjusted basis, diluted earnings per share increased 23% to $0.43. Full year diluted earnings per share increased 46% to $2.07. On an adjusted basis, diluted earnings per share increased 43% to $2.02.
  • Cash and cash equivalents decreased to $295.1 million from $469.5 million as of September 30, 2025. The decrease was primarily driven by the retirement of SMG’s existing third-party indebtedness of $134.2 million and cash used for acquisitions.

SEGMENT RESULTS

U.S. Pawn

  • PLO ended the year at $269.4 million, an increase of 15% (13% on a same-store basis) driven by higher average loan size, as rising gold prices resulted in higher jewelry collateral value.
  • Fourth quarter total revenues increased 14% and gross profit increased 12%, driven by increased jewelry scrap sales, PSC, and merchandise sales. Full year total revenues increased 18% and gross profit increased 17%.
  • PSC increased 12% for the quarter and full year as a result of higher average PLO.
  • Fourth quarter merchandise sales increased 7% (5% on a same-store basis), and sales gross margin increased by 160 bps to 39%. Full year merchandise sales increased 8% and merchandise sales gross profit margin increased by 150 bps to 39%.
  • Fourth quarter jewelry scrap sales increased 46% due to increase in gold price and jewelry purchases, and jewelry scrap sales gross margin decreased to 21% from 30% (as the gold price declined from third quarter levels, compared to a sharp increase during the prior year quarter). Full year jewelry scrap sales increased 100%, and jewelry scrap sales gross margin increased to 32% from 27% due to increase in gold price and jewelry purchases.
  • Net inventory increased 31% (27% on a same-store basis) due to increase in PLO, layaways and purchases. Inventory turnover decreased from 2.1x to 1.9x for the quarter, and 2.2x to 2.1x for the full year. Aged general merchandise decreased by 61 bps to 1.9%, or $0.8 million of total general merchandise inventory.
  • Fourth quarter store expenses increased 1% (decreased 1% on a same-store basis). Full year store expenses increased 6% (4% on a same-store basis).
  • Segment contribution increased 29% to $70.3 million in the fourth quarter and increased 35% to $280.7 million for the full year.
  • Segment store count increased to 563 due to the acquisition of 5 stores and the consolidation of 2 stores during the quarter.

Latin America Pawn

  • PLO increased 35% to $99.6 million (33% on a constant currency basis). On a same-store basis, PLO increased 25% (24% increase on a constant currency basis) due to strong loan demand and improved operational performance.
  • Fourth quarter total revenues increased 36% (28% on constant currency basis), and gross profit increased 35% (28% on a constant currency basis), primarily due to increased jewelry scrap sales, PSC and merchandise sales. Full year total revenues were up 33% (23% on a constant currency basis), while gross profit increased 39% (28% on a constant currency basis).
  • PSC increased in the fourth quarter to $44.9 million, an increase of 33% (25% on a constant currency basis) as a result of higher average PLO. For the full year PSC increased 32% (23% on a constant currency basis).
  • Fourth quarter merchandise sales increased 31% (23% on a constant currency basis) and 24% on a same-store basis (17% increase on a constant currency basis). Merchandise sales gross margin increased to 36% from 32%. For the full year, merchandise sales increased 29% (19% on a constant currency basis) and merchandise gross margin increased 420 bps to 35%.
  • Fourth quarter jewelry scrap sales increased 118% to $10.3 million (108% on a constant currency basis) due to the increase in gold price, and jewelry scrap sales gross profit decreased to $0.8 million (with a 7% margin) from $1.3 million (with a 27% margin), as the gold price declined from third quarter levels, compared to a sharp increase during the prior year quarter. Full year jewelry scrap sales increased 119% to $29.0 million (100% on a constant currency basis), and jewelry scrap sales margin decreased to 23% from 26%.
  • Net inventory increased 32% (31% on a constant currency basis) due to an increase in PLO. For the quarter, inventory turnover remained consistent at 2.9x and increased to 3.1x from 3.0x for the full year. On a same-store basis, net inventory increased by 22% (21% on a constant currency basis). Aged general merchandise decreased below 1% of total general merchandise inventory.
  • Fourth quarter store expenses increased 26% (19% on a constant currency basis) and increased 17% on a same-store basis (10% on a constant currency basis); and for the full year store expenses increased 36% (25% on a constant currency basis) and 25% (15% on a constant currency basis) on a same-store basis due to increased labor, in line with store activity and minimum wage increases.
  • Fourth quarter segment contribution increased 56% to $24.4 million (49% on a constant currency basis to $23.4 million). Full year segment contribution was up 46% to $88.5 million (35% on a constant currency basis).
  • Segment store count increased by 41 stores to 922 during the quarter due to 25 de novo stores and 17 acquired stores, partially offset by 1 store consolidation.

SMG

  • The second quarter of fiscal 2026 represents the first quarter of SMG consolidation. In the fourth quarter, we acquired the remaining shares of SMG, making it wholly owned. As SMG was not owned during the comparable prior-year period, results are presented on an absolute basis without year-over-year comparisons.
  • PLO of $33.7 million and net inventory of $31.3 million, with aged general merchandise at 1.5% of total general merchandise inventory.
  • Fourth quarter total revenues were $42.3 million, comprised of merchandise sales of $17.4 million (with a margin of 26%), PSC of $14.6 million, and jewelry scrap sales of $10.3 million (with a margin of 22%). Full year total revenues were $136.7 million, comprised of merchandise sales of $52.3 million (with a margin of 30%), PSC of $43.3 million, and jewelry scrap sales of $41.1 million (with a margin of 26%).
  • Fourth quarter store expenses totaled $15.5 million, and full year store expenses totaled $48.2 million.
  • Fourth quarter segment contribution was $4.3 million, and full year segment contribution was $19.0 million.
  • Segment store count at 105 due to the consolidation of 1 store and closure of 2 stores during the quarter.

FORM 10-K

EZCORP expects to file its Annual Report on Form 10-K for the year ended September 30, 2026 with the Securities and Exchange Commission on or about November 12, 2026. The report will be available in the Investor Relations section of the Company’s website at http://investors.ezcorp.com.

CONFERENCE CALL

EZCORP will host a conference call on Thursday, November 12, 2026, at 8:00 am Central Time to discuss fourth quarter and full year fiscal 2026 results. Analysts and institutional investors may participate on the conference call by registering online at https://register-conf.media-server.com/register/BId30caa98675c4f6eb98946e8a60dbfeb. Once registered you will receive the dial-in details with a unique PIN to join the call. The conference call will be webcast simultaneously to the public through this link: https://edge.media-server.com/mmc/p/v2jhz4kh. A replay of the conference call will be available online at http://investors.ezcorp.com shortly after the end of the call. 

ABOUT EZCORP

Formed in 1989, EZCORP is a leading provider of pawn transactions in the United States, Latin America and the Caribbean. We also sell pre-owned and recycled merchandise, primarily collateral forfeited from pawn lending operations and merchandise purchased from customers. We are dedicated to satisfying the short-term cash needs of consumers who are both cash and credit constrained, focusing on an industry-leading customer experience. EZCORP is traded on NASDAQ under the symbol EZPW.

Follow us on social media:

Facebook EZPAWN Official https://www.facebook.com/EZPAWN/

EZCORP Instagram Official https://www.instagram.com/ezcorp_official/

EZPAWN Instagram Official https://www.instagram.com/ezpawnofficial/

EZCORP LinkedIn https://www.linkedin.com/company/ezcorp/

FORWARD LOOKING STATEMENTS

This announcement contains certain forward-looking statements regarding the Company’s strategy, initiatives and expected performance. These statements are based on the Company’s current expectations as to the outcome and timing of future events. All statements, other than statements of historical facts, including all statements regarding the Company’s strategy, initiatives and future performance, that address activities or results that the Company plans, expects, believes, projects, estimates or anticipates, will, should or may occur in the future, including future financial or operating results, are forward-looking statements. Actual results for future periods may differ materially from those expressed or implied by these forward-looking statements due to a number of uncertainties and other factors, including operating risks, liquidity risks, legislative or regulatory developments, market factors, current or future litigation and risks associated with pandemics. For a discussion of these and other factors affecting the Company’s business and prospects, see the Company’s annual, quarterly and other reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.

Contact:
Email: Investor_Relations@ezcorp.com
Phone: (512) 314-2220

Note: Percentages are calculated from the underlying numbers in thousands and, as a result, may not agree to the percentages calculated from numbers in millions. Numbers may not foot or cross foot due to rounding.
1 “Adjusted” basis, which is a non-GAAP measure, excludes certain items. “Constant currency” basis, which is a non-GAAP measure, excludes the impact of foreign currency exchange rate fluctuations. For additional information about these calculations, as well as a reconciliation to the most comparable GAAP financial measures, see “Non-GAAP Financial Information” at the end of this release.
2 “Same-store” basis, which is a financial measure, includes stores open the entirety of the comparable periods.


EZCORP, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

    Three Months Ended
September 30,
  Twelve Months Ended
September 30,
(in thousands, except per share amount)     2026       2025       2026       2025  
Revenues:                
Merchandise sales   $ 220,704     $ 176,565     $ 854,971     $ 700,999  
Pawn service charges     162,685       125,966       598,205       474,228  
Core pawn revenues     383,389       302,531       1,453,176       1,175,227  
Jewelry scrap sales     63,640       34,244       241,364       98,884  
Other revenues     33       38       170       169  
Total revenues     447,062       336,813       1,694,710       1,274,280  
Merchandise cost of goods sold     139,803       114,072       540,102       455,677  
Core pawn gross profit     243,619       188,497       913,244       719,719  
Jewelry scrap cost of goods sold     51,481       24,171       169,639       72,538  
Gross profit     255,778       198,570       984,969       746,065  
Operating expenses:                
Store expenses     148,975       122,993       571,559       458,378  
General and administrative     38,239       29,425       133,469       106,230  
Impairment of other assets     1,723       877       1,723       877  
Depreciation and amortization     10,296       8,180       38,290       32,538  
Loss on sale or disposal of assets and other     169       110       281       135  
Other operating income     —       —       —       (1,262 )
Total operating expenses     199,402       161,585       745,322       596,896  
Operating income     56,376       36,985       239,647       149,169  
Interest expense     8,923       8,143       33,796       23,029  
Interest income     (2,252 )     (5,313 )     (12,439 )     (14,721 )
Equity in net income of unconsolidated affiliates     (723 )     (1,970 )     (5,607 )     (6,150 )
Other (income) expense     2,756       (139 )     (441 )     238  
Income before income taxes     47,672       36,264       224,338       146,773  
Income tax expense     13,465       9,560       57,749       37,160  
Consolidated net income   $ 34,207     $ 26,704     $ 166,589     $ 109,613  
Consolidated net (income) attributable to non-controlling interest     96       —       (680 )     —  
Consolidated net income attributable to EZCORP     34,303       26,704       165,909       109,613  
                 
Basic earnings per share attributable to EZCORP   $ 0.56     $ 0.44     $ 2.70     $ 1.91  
Diluted earnings per share attributable to EZCORP   $ 0.43     $ 0.34     $ 2.07     $ 1.42  
                 
Weighted-average basic shares outstanding     61,424       60,901       61,463       57,466  
Weighted-average diluted shares outstanding     83,799       83,218       83,724       83,383  


EZCORP, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

(in thousands, except per share amount)   September 30, 2026   September 30, 2025
Assets:        
Current assets:        
Cash and cash equivalents   $ 295,116     $ 469,524  
Short-term restricted cash     2,358       525  
Pawn loans     402,761       307,496  
Pawn service charges receivable, net     61,821       48,733  
Inventory, net     358,348       248,457  
Prepaid expenses and other current assets     37,597       51,221  
Total current assets     1,158,001       1,125,956  
Investments in unconsolidated affiliates     25,470       18,123  
Other investments     6,883       51,903  
Property and equipment, net     96,574       75,331  
Right-of-use assets     292,924       236,462  
Long-term restricted cash     13,876       14,664  
Goodwill     479,173       324,889  
Intangible assets, net     123,473       58,832  
Deferred tax asset, net     19,049       29,455  
Other assets, net     18,415       15,594  
Total assets   $ 2,233,838     $ 1,951,209  
         
Liabilities and equity:        
Current liabilities:        
Accounts payable, accrued expenses and other current liabilities     138,463       105,443  
Customer layaway deposits     45,198       33,901  
Operating lease liabilities, current     71,293       61,228  
Total current liabilities     254,954       200,572  
Long-term debt, net     520,008       518,076  
Deferred tax liability, net     2,344       2,571  
Operating lease liabilities     233,793       184,736  
Other long-term liabilities     29,552       19,769  
Total liabilities     1,040,651       925,724  
Commitments and contingencies        
Stockholders’ equity:        
Class A Non-Voting Common Stock, par value $0.01 per share; shares authorized: 100,000,000; issued and outstanding: 58,409,584 as of September 30, 2026 and 57,921,451 as of September 30, 2025     584       579  
Class B Voting Common Stock, convertible, par value $0.01 per share; shares authorized: 3,000,000; issued and outstanding: 2,970,171 as of September 30, 2026 and 2025     30       30  
Additional paid-in capital     457,618       450,892  
Retained earnings     771,832       612,687  
Accumulated other comprehensive loss     (37,623 )     (38,703 )
Total EZCORP equity     1,192,441       1,025,485  
Non-controlling interest     746       —  
Total equity     1,193,187       1,025,485  
Total liabilities and equity   $ 2,233,838     $ 1,951,209  


EZCORP, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

    Twelve Months Ended
September 30,
(in thousands)     2026       2025  
     
Operating activities:        
Net income   $ 166,589     $ 109,613  
Adjustments to reconcile net income to net cash flows from operating activities:        
Depreciation and amortization     38,290       32,538  
Amortization of deferred financing costs     1,932       1,726  
Non-cash lease expense     69,172       59,265  
Deferred income taxes     (2,455 )     (3,084 )
Impairment of other assets     1,723       877  
Other adjustments     894       (1,942 )
Provision for inventory reserve     (451 )     858  
Stock compensation expense     16,790       12,465  
Equity in net income from investment in unconsolidated affiliates     (5,607 )     (6,150 )
Gain from remeasurement of previously held equity interest     (1,179 )     —  
Changes in operating assets and liabilities, net of business acquisitions:        
Pawn service charges receivable     (7,022 )     (3,833 )
Inventory     (35,807 )     (18,179 )
Prepaid expenses, other current assets and other assets     7,744       (5,719 )
Accounts payable, accrued expenses and other liabilities     (68,786 )     (41,420 )
Customer layaway deposits     9,218       11,712  
Income taxes     (4,880 )     258  
Net cash provided by operating activities     186,165       148,985  
Investing activities:        
Loans made     (1,312,115 )     (1,006,505 )
Loans repaid     723,174       557,761  
Recovery of pawn loan principal through sale of forfeited collateral     496,738       393,203  
Capital expenditures     (45,405 )     (38,561 )
Acquisitions, net of cash acquired     (41,010 )     (20,693 )
Issuance of notes receivable     (9,000 )     (5,895 )
Investment in unconsolidated affiliate     (7,584 )     (786 )
Dividends from unconsolidated affiliates     3,929       3,614  
Net cash used in investing activities     (191,273 )     (117,862 )
Financing activities:        
Taxes paid related to net share settlement of equity awards     (6,371 )     (3,972 )
Proceeds from issuance of debt     —       300,000  
Debt issuance cost     —       (7,593 )
Payments on debt     (134,151 )     (6,410 )
Purchase and retirement of treasury stock     (11,036 )     (6,999 )
Payment of contingent consideration     (554 )     —  
Acquisition of non-controlling interest     (15,441 )     —  
Payments of finance leases     (945 )     (606 )
Net cash (used in) provided by financing activities     (168,498 )     274,420  
Effect of exchange rate changes on cash and cash equivalents and restricted cash     243       (637 )
Net (decrease) increase in cash, cash equivalents and restricted cash     (173,363 )     304,906  
Cash and cash equivalents and restricted cash at beginning of period     484,713       179,807  
Cash and cash equivalents and restricted cash at end of period   $ 311,350     $ 484,713  

                 

EZCORP, Inc.
OPERATING SEGMENT RESULTS
(Unaudited)

As a result of the acquisition of Founders One, LLC and its subsidiary Simple Management Group, Inc. effective January 2, 2026, the composition of our reportable segments changed beginning in the second quarter of fiscal 2026. SMG is now reported as a standalone reportable segment. Our equity interest in Cash Converters International Limited is now included within Corporate. Prior period segment information has been recast to reclassify Cash Converters equity income and interest income from notes receivable from Founders from the ‘Other Investments’ segment to Corporate. Because SMG was not a consolidated subsidiary in any prior period presented, no prior period SMG segment results exist.

    Three Months Ended September 30, 2026
(in thousands)   U.S. Pawn   Latin America
Pawn
  SMG   Total
Segments
  Corporate
Items
  Consolidated
                         
Revenues:                        
Merchandise sales   $ 125,814     $ 77,506     $ 17,384   $ 220,704   $ —     $ 220,704  
Jewelry scrap sales     43,000       10,295       10,345     63,640     —       63,640  
Pawn service charges     103,224       44,889       14,572     162,685     —       162,685  
Other revenues     17       16       —     33     —       33  
Total revenues     272,055       132,706       42,301     447,062     —       447,062  
Merchandise cost of goods sold     76,976       50,010       12,817     139,803     —       139,803  
Jewelry scrap cost of goods sold     33,882       9,537       8,062     51,481     —       51,481  
Gross profit     161,197       73,159       21,422     255,778     —       255,778  
Segment and corporate expenses (income):                        
Store expenses     88,019       45,438       15,518     148,975     —       148,975  
General and administrative     —       —       —     —     38,239       38,239  
Impairment of other assets     —       —       —     —     1,723       1,723  
Depreciation and amortization     2,945       3,049       1,087     7,081     3,215       10,296  
Loss on sale or disposal of assets and other     (4 )     (2 )     175     169     —       169  
Interest expense     —       —       —     —     8,923       8,923  
Interest income     —       —       —     —     (2,252 )     (2,252 )
Equity in net income of unconsolidated affiliates     —       —       —     —     (723 )     (723 )
Other (income) expense     (45 )     231       368     554     2,202       2,756  
Segment contribution   $ 70,282     $ 24,443     $ 4,274   $ 98,999        
Income (loss) before income taxes               $ 98,999   $ (51,327 )   $ 47,672  

    Three Months Ended September 30, 2025
(in thousands)   U.S. Pawn   Latin America
Pawn
  Total
Segments
  Corporate
Items
  Consolidated
                     
Revenues:                    
Merchandise sales   $ 117,288   $ 59,277     $ 176,565     $ —     $ 176,565  
Jewelry scrap sales     29,512     4,732       34,244       —       34,244  
Pawn service charges     92,125     33,841       125,966       —       125,966  
Other revenues     21     17       38       —       38  
Total revenues     238,946     97,867       336,813       —       336,813  
Merchandise cost of goods sold     73,694     40,377       114,071       —       114,071  
Jewelry scrap cost of goods sold     20,729     3,442       24,171       —       24,171  
Gross profit     144,523     54,048       198,571       —       198,571  
Segment and corporate expenses (income):                    
Store expenses     87,006     35,987       122,993       —       122,993  
General and administrative     —     —       —       29,425       29,425  
Impairment of other assets     263     —       263       614       877  
Depreciation and amortization     2,701     2,421       5,122       3,059       8,181  
Loss on sale or disposal of assets and other     66     44       110       —       110  
Interest expense     —     —       —       8,143       8,143  
Interest income (a)     —     —       —       (5,313 )     (5,313 )
Equity in net income of unconsolidated affiliates (b)     —     —       —       (1,970 )     (1,970 )
Other (income) expense     7     (110 )     (103 )     (36 )     (139 )
Segment contribution   $ 54,480   $ 15,706     $ 70,186          
Income (loss) before income taxes           $ 70,186     $ (33,922 )   $ 36,264  

(a) Interest income includes $0.8 million of interest income from notes receivable from Founders, which has been recast from the “Other Investments” segment to Corporate to conform to the current period presentation.
(b) Equity in net income of unconsolidated affiliates includes $2.0 million of equity income from CCV, which has been recast from the “Other Investments” segment to Corporate to conform to the current period presentation.

    Twelve Months Ended September 30, 2026
(in thousands)   U.S. Pawn   Latin America
Pawn
  SMG   Total
Segments
  Corporate
Items
  Consolidated
                         
Revenues:                        
Merchandise sales   $ 511,502     $ 291,149     $ 52,320   $ 854,971     $ —     $ 854,971  
Jewelry scrap sales     171,236       28,999       41,129     241,364       —       241,364  
Pawn service charges     392,377       162,557       43,271     598,205       —       598,205  
Other revenues     107       63       —     170       —       170  
Total revenues     1,075,222       482,768       136,720     1,694,710       —       1,694,710  
Merchandise cost of goods sold     313,840       189,783       36,479     540,102       —       540,102  
Jewelry scrap cost of goods sold     117,087       22,308       30,244     169,639       —       169,639  
Gross profit     644,295       270,677       69,997     984,969       —       984,969  
Segment and corporate expenses (income):                        
Store expenses     352,201       171,200       48,158     571,559       —       571,559  
General and administrative     —       —       —     —       133,469       133,469  
Impairment of other assets     —       —       —     —       1,723       1,723  
Depreciation and amortization     11,314       11,208       2,396     24,918       13,372       38,290  
Loss on sale or disposal of assets and other     87       19       175     281       —       281  
Interest expense     —       —       —     —       33,796       33,796  
Interest income (c)     —       —       —     —       (12,439 )     (12,439 )
Equity in net income of unconsolidated affiliates (d)     —       —       —     —       (5,607 )     (5,607 )
Other (income) expense     (45 )     (258 )     249     (54 )     (387 )     (441 )
Segment contribution   $ 280,738     $ 88,508     $ 19,019   $ 388,265          
Income (loss) before income taxes               $ 388,265     $ (163,927 )   $ 224,338  

(c) Interest income includes $1.0 million of interest income from notes receivable from Founders recorded in the first quarter of fiscal 2026, which has been recast from the “Other Investments” segment to Corporate to conform to the current period presentation.
(d) Equity in net income of unconsolidated affiliates includes $1.8 million of equity income from CCV recorded in the first quarter of fiscal 2026, which has been recast from the “Other Investments” segment to Corporate to conform to the current period presentation.

    Twelve Months Ended September 30, 2025
(in thousands)   U.S. Pawn   Latin America
Pawn
  Total
Segments
  Corporate
Items
  Consolidated
                     
Revenues:                    
Merchandise sales   $ 475,252   $ 225,747     $ 700,999     $ —     $ 700,999  
Jewelry scrap sales     85,658     13,226       98,884       —       98,884  
Pawn service charges     351,479     122,749       474,228       —       474,228  
Other revenues     103     66       169       —       169  
Total revenues     912,492     361,788       1,274,280       —       1,274,280  
Merchandise cost of goods sold     299,107     156,570       455,677       —       455,677  
Jewelry scrap cost of goods sold     62,746     9,792       72,538       —       72,538  
Gross profit     550,639     195,426       746,065       —       746,065  
Segment and corporate expenses (income):                    
Store expenses     332,048     126,330       458,378       —       458,378  
General and administrative     —     —       —       106,230       106,230  
Impairment of other assets     263     —       263       614       877  
Depreciation and amortization     10,750     8,612       19,362       13,176       32,538  
Loss on sale or disposal of assets and other     83     52       135       —       135  
Other operating income     —     —       —       (1,262 )     (1,262 )
Interest expense     —     —       —       23,029       23,029  
Interest income (e)     —     —       —       (14,721 )     (14,721 )
Equity in net income of unconsolidated affiliates (f)     —     —       —       (6,150 )     (6,150 )
Other (income) expense     —     (330 )     (330 )     568       238  
Segment contribution   $ 207,495   $ 60,762     $ 268,257          
Income (loss) before income taxes           $ 268,257     $ (121,484 )   $ 146,773  

(e) Interest income includes $2.6 million of interest income from notes receivable from Founders, which has been recast from the “Other Investments” segment to Corporate to conform to the current period presentation.
(f) Equity in net income of unconsolidated affiliates includes $6.9 million of equity income from CCV, which has been recast from the “Other Investments” segment to Corporate to conform to the current period presentation.


EZCORP, Inc.

STORE COUNT ACTIVITY
(Unaudited)

  Twelve Months Ended September 30, 2026
  U.S. Pawn   Latin America
Pawn
  SMG   Consolidated
               
As of September 30, 2025 545     815     —     1,360  
New locations opened —     7     —     7  
Locations acquired 3     14     —     17  
Locations combined or closed (1 )   —     —     (1 )
As of December 31, 2025 547     836     —     1,383  
New locations opened —     4     2     6  
Locations acquired 12     —     105     117  
As of March 31, 2026 559     840     107     1,506  
New locations opened —     9     1     10  
Locations acquired 1     33     —     34  
Locations combined or closed —     (1 )   —     (1 )
As of June 30, 2026 560     881     108     1,549  
New locations opened —     25     —     25  
Locations acquired 5     17     —     22  
Locations combined or closed (2 )   (1 )   (3 )   (6 )
As of September 30, 2026 563     922     105     1,590  

  Twelve Months Ended September 30, 2025
  U.S. Pawn   Latin America
Pawn
  Consolidated
           
As of September 30, 2024 542     737     1,279  
New locations opened —     4     4  
As of December 31, 2024 542     741     1,283  
New locations opened —     9     9  
Locations acquired —     1     1  
Locations combined or closed —     (9 )   (9 )
As of March 31, 2025 542     742     1,284  
New locations opened —     10     10  
Locations acquired 3     40     43  
Locations combined or closed —     (1 )   (1 )
As of June 30, 2025 545     791     1,336  
New locations opened —     17     17  
Locations acquired 1     7     8  
Locations combined or closed (1 )   —     (1 )
As of September 30, 2025 545     815     1,360  


Non-GAAP Financial Information (Unaudited)

In addition to the financial information prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), we provide certain other non-GAAP financial information on a constant currency (“constant currency”) and adjusted basis. We use constant currency results to evaluate our Latin America Pawn operations, which are denominated primarily in Mexican pesos, Guatemalan quetzales and other Latin American currencies. We believe that presentation of constant currency and adjusted results is meaningful and useful in understanding the activities and business metrics of our operations and reflects an additional way of viewing aspects of our business that, when viewed with GAAP results, provides a more complete understanding of factors and trends affecting our business. We provide non-GAAP financial information for informational purposes and to enhance understanding of our GAAP consolidated financial statements. We use this non-GAAP financial information primarily to evaluate and compare operating results across accounting periods.

Readers should consider the information in addition to, but not instead of or superior to, our financial statements prepared in accordance with GAAP. This non-GAAP financial information may be determined or calculated differently by other companies, limiting the usefulness of those measures for comparative purposes.

Constant currency results reported herein are calculated by translating consolidated balance sheet and consolidated statement of operations items denominated in local currency to U.S. dollars using the exchange rate from the prior-year comparable period, as opposed to the current period, in order to exclude the effects of foreign currency rate fluctuations. In addition, we have an equity method investment that is denominated in Australian dollars and is translated into U.S. dollars. We used the end-of-period rate for balance sheet items and the average closing daily exchange rate on a monthly basis during the appropriate period for statement of operations items. The end-of-period and approximate average exchange rates for each applicable currency as compared to U.S. dollars as of and for the three and twelve months ended September 30, 2026 and 2025 were as follows:

  September 30,   Three Months Ended
September 30,
  Twelve Months Ended
September 30,
  2026   2025   2026   2025   2026   2025
                       
Mexican peso 18.1   18.3   17.3   18.6   17.6   19.7
Guatemalan quetzal 7.5   7.5   7.5   7.6   7.5   7.6
Honduran lempira 26.4   25.9   26.5   25.9   26.3   25.4
Australian dollar 1.4   1.5   1.4   1.5   1.4   1.6

Our statement of operations constant currency results reflect the monthly exchange rate fluctuations and so are not directly calculable from the above rates. Constant currency results, where presented, also exclude the foreign currency gain or loss.

Miscellaneous Non-GAAP Financial Measures

  Three Months Ended
September 30,
  Twelve Months Ended
September 30,
    2026       2025       2026       2025  
               
Consolidated net income $ 34.2     $ 26.7     $ 166.6     $ 109.6  
Interest expense   8.9       8.1       33.8       23.0  
Interest income   (2.3 )     (5.3 )     (12.4 )     (14.7 )
Income tax expense   13.5       9.6       57.7       37.2  
Depreciation and amortization   10.3       8.2       38.3       32.5  
EBITDA $ 64.6     $ 47.3     $ 284.0     $ 187.6  

  Total
Revenues
  Gross
Profit
  Income
Before Tax
  Tax
Effect
  Consolidated
Net Income
  NCI   Net Income
net of NCI
  Diluted
EPS
  EBITDA
2026 Q4 Reported $ 447.1     $ 255.8     $ 47.7     $ 13.5     $ 34.2     $ 0.1     $ 34.3     $ 0.43     $ 64.6  
Tax discrete adjustments   —       —       —       (0.1 )     0.1       —       0.1       —       —  
Contract termination   —       —       (2.0 )     (0.5 )     (1.5 )     —       (1.5 )     (0.02 )     (2.0 )
Corporate office impairment   —       —       1.7       0.4       1.3       —       1.3       0.02       1.7  
Founders value adjustment   —       —       0.4       0.1       0.3       —       0.3       0.01       0.4  
FX impact   —       —       0.4       0.1       0.3       —       0.3       —       0.4  
Constant Currency   (7.3 )     (4.1 )     (1.0 )     (0.3 )     (0.7 )     —       (0.7 )     (0.01 )     (1.1 )
2026 Q4 Adjusted $ 439.8     $ 251.7     $ 47.2     $ 13.2     $ 34.0     $ 0.1     $ 34.1     $ 0.43     $ 64.0  
                                   
                                   
  Total
Revenues
  Gross
Profit
  Income
Before Tax
  Tax
Effect
  Consolidated
Net Income
  NCI   Net Income
net of NCI
  Diluted
EPS
  EBITDA
2026 Full Year Reported $ 1,694.7     $ 985.0     $ 224.3     $ 57.7     $ 166.6     $ (0.7 )   $ 165.9     $ 2.07     $ 284.0  
Non-recurring foreign tax expense   —       —       —       (0.5 )     0.5       —       0.5       0.01       —  
Tax discrete adjustments   —       —       —       (0.1 )     0.1       —       0.1       —       —  
Contract termination   —       —       (2.0 )     (0.5 )     (1.5 )     —       (1.5 )     (0.02 )     (2.0 )
Corporate office impairment   —       —       1.7       0.4       1.3       —       1.3       0.02       1.7  
Corporate lease termination   —       —       (0.6 )     (0.1 )     (0.5 )     —       (0.5 )     (0.01 )     (0.6 )
Founders value adjustment   —       —       (1.2 )     (0.3 )     (0.9 )     —       (0.9 )     (0.01 )     (1.2 )
FX impact   —       —       (0.1 )     —       (0.1 )     —       (0.1 )     —       (0.1 )
Constant Currency   (37.1 )     (20.7 )     (4.3 )     (1.2 )     (3.1 )     —       (3.1 )     (0.04 )     (5.1 )
2026 Full Year Adjusted $ 1,657.6     $ 964.3     $ 217.8     $ 55.4     $ 162.4     $ (0.7 )   $ 161.7     $ 2.02     $ 276.7  

  Total
Revenues
  Gross
Profit
  Income
Before Tax
  Tax
Effect
  Consolidated
Net Income
  NCI   Net Income
net of NCI
  Diluted
EPS
  EBITDA
2025 Q4 Reported $ 336.8   $ 198.6   $ 36.3     $ 9.6     $ 26.7     $ —   $ 26.7     $ 0.34     $ 47.3  
Corporate office impairment   —     —     0.6       0.1       0.5       —     0.5       0.01       0.6  
Tax discrete adjustments   —     —     —       (0.6 )     0.6       —     0.6       0.01       —  
Non-recurring foreign tax expense   —     —     —       1.0       (1.0 )     —     (1.0 )     (0.01 )     —  
FX impact   —     —     0.1       —       0.1       —     0.1       —       0.1  
2025 Q4 Adjusted $ 336.8   $ 198.6   $ 37.0     $ 10.1     $ 26.9     $ —   $ 26.9     $ 0.35     $ 48.0  
                                   
                                   
  Total
Revenues
  Gross
Profit
  Income
Before Tax
  Tax
Effect
  Consolidated
Net Income
  NCI   Net Income
net of NCI
  Diluted
EPS
  EBITDA
2025 Full Year Reported $ 1,274.3   $ 746.1   $ 146.8     $ 37.2     $ 109.6     $ —   $ 109.6     $ 1.42     $ 187.6  
Corporate lease termination   —     —     (1.3 )     (0.3 )     (1.0 )     —     (1.0 )     (0.01 )     (1.3 )
Corporate office impairment   —     —     0.6       0.2       0.4       —     0.4       —       0.6  
Tax discrete adjustments   —     —     —       0.5       (0.5 )     —     (0.5 )     (0.01 )     —  
Non-recurring foreign tax expense   —     —     —       0.7       (0.7 )     —     (0.7 )     (0.01 )     —  
FX impact   —     —     0.9       0.2       0.7       —     0.7       0.02       1.0  
2025 Full Year Adjusted $ 1,274.3   $ 746.1   $ 147.0     $ 38.5     $ 108.5     $ —   $ 108.5     $ 1.41     $ 187.9  

  Three Months Ended
September 30, 2026
  Twelve Months Ended
September 30, 2026
(in millions) U.S. Dollar
Amount
  Percentage
Change YOY
  U.S. Dollar
Amount
  Percentage
Change YOY
               
Consolidated revenues $ 447.1     33 %   $ 1,694.7     33 %
Currency exchange rate fluctuations   (7.3 )         (37.1 )    
Constant currency consolidated revenues $ 439.8     31 %   $ 1,657.6     30 %
               
Consolidated gross profit $ 255.8     29 %   $ 985.0     32 %
Currency exchange rate fluctuations   (4.1 )         (20.7 )    
Constant currency consolidated gross profit $ 251.7     27 %   $ 964.3     29 %
               
Consolidated net inventory $ 358.3     44 %   $ 358.3     44 %
Currency exchange rate fluctuations   (1.0 )         (1.0 )    
Constant currency consolidated net inventory $ 357.3     44 %   $ 357.3     44 %
               
Latin America Pawn gross profit $ 73.2     35 %   $ 270.7     39 %
Currency exchange rate fluctuations   (4.1 )         (20.7 )    
Constant currency Latin America Pawn gross profit $ 69.1     28 %   $ 250.0     28 %
               
Latin America Pawn PLO $ 99.6     35 %   $ 99.6     35 %
Currency exchange rate fluctuations   (1.2 )         (1.2 )    
Constant currency Latin America Pawn PLO $ 98.4     33 %   $ 98.4     33 %
               
Latin America Pawn PSC revenues $ 44.9     33 %   $ 162.6     32 %
Currency exchange rate fluctuations   (2.5 )         (11.9 )    
Constant currency Latin America Pawn PSC revenues $ 42.4     25 %   $ 150.7     23 %
               
Latin America Pawn merchandise sales $ 77.5     31 %   $ 291.1     29 %
Currency exchange rate fluctuations   (4.4 )         (22.7 )    
Constant currency Latin America Pawn merchandise sales $ 73.1     23 %   $ 268.4     19 %
               
Latin America Pawn segment profit before tax $ 24.4     56 %   $ 88.5     46 %
Currency exchange rate fluctuations   (1.0 )         (6.2 )    
Constant currency Latin America Pawn segment profit before tax $ 23.4     49 %   $ 82.3     35 %

MONTREAL, Nov. 11, 2026 (GLOBE NEWSWIRE) — OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX & NYSE) is pleased to announce that the Company’s Board of Directors has approved a fourth quarter 2026 dividend of US$0.065 per common share. The dividend will be paid on January 15, 2027 to shareholders of record as of the close of business on December 31, 2026. This dividend is an “eligible dividend” as defined in the Income Tax Act (Canada).

For shareholders residing in Canada, the Canadian dollar equivalent will be determined based on the daily rate published by the Bank of Canada on the record date or, if the Bank of Canada does not publish a rate on that date, on the most recent preceding business day.

Dividend Reinvestment Plan

The Company also wishes to remind its shareholders that it has implemented a dividend reinvestment plan (the “Plan”). Shareholders who are residents of Canada and the United States may elect to participate in the Plan in connection with the dividend to be paid on January 15, 2027 to shareholders on record as of December 31, 2026, and consequently benefit from the 3% discount offered for the fourth quarter dividend. More details are available on OR Royalties’ website at https://orroyalties.com/English/investor-relations/stock-information/dividend/default.aspx.

Non-registered beneficial shareholders who wish to participate in the Plan should contact their financial advisor, broker, investment dealer, bank or other financial institution that holds their common shares to inquire about the applicable enrolment deadline and to request enrolment in the Plan. For more information on how to enroll or any other inquiries, contact our transfer agent at 1-800-387-0825 (toll-free in Canada) or shareholderinquiries@tmx.com.

Participation in the Plan does not relieve shareholders of any liability for taxes that may be payable in respect of dividends that are reinvested in common shares under the Plan. Shareholders should consult their tax advisors concerning the tax implications of their participation in the Plan having regard to their particular circumstances.

This press release is not an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction.

About OR Royalties Inc.

OR Royalties is a precious metals royalty and streaming company focused on Tier-1 mining jurisdictions defined as Canada, the United States, and Australia. OR Royalties commenced activities in June 2014 with a single producing asset, and today holds a portfolio of over 200 royalties, streams and similar interests. OR Royalties’ portfolio is anchored by its cornerstone asset, the 3-5% net smelter return royalty on Agnico Eagle Mines Ltd.’s Canadian Malartic Complex, one of the world’s largest gold mines.

OR Royalties’ head office is located at 1100 Avenue des Canadiens-de-Montréal, Suite 300, Montréal, Québec, H3B 2S2.

For further information, please contact OR Royalties Inc.
Grant Moenting
Vice President, Capital Markets
Cell: (365) 275-1954
Email: gmoenting@ORroyalties.com
Heather Taylor
Vice President, Sustainability and Communications
Tel: (647) 477-2087
Email: htaylor@ORroyalties.com
   

Forward-looking statements

Certain statements contained in this press release may be deemed “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” within the meaning of applicable Canadian securities legislation. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Forward-looking statements are not guarantees of performance. In this news release, these forward-looking statements may involve, but are not limited to, comments with respect to the directors and officers of the Company, information pertaining to the fact that all conditions for payment of the dividend will be met and that such dividend will continue to be an “eligible dividend” as defined in the Income Tax Act (Canada). Words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including that the financial situation of the Company will remain favourable. The Company considers its assumptions to be reasonable based on information currently available, but cautions the reader that its assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business.

For additional information with respect to these and other factors and assumptions underlying the forward-looking statements made in this press release, see the section entitled “Risk Factors” in the most recent Annual Information Form of OR Royalties which is filed with the Canadian securities commissions and available electronically under OR Royalties’ issuer profile on SEDAR+ at www.sedarplus.com and with the U.S. Securities and Exchange Commission and available electronically under OR Royalties’ issuer profile on EDGAR at www.sec.gov. The forward-looking information set forth herein reflects OR Royalties’ expectations as at the date of this press release and is subject to change after such date. OR Royalties disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

MIAMI, Nov. 11, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it has rescheduled its third quarter 2026 financial results conference call and webcast to 4:30 p.m. Eastern Time, after the close of U.S. financial markets on Thursday, November 12, 2026, from its previously announced time of 8:30 a.m. Eastern Time.

The revised timing will allow management to provide investors with a more comprehensive update on the Company’s recent developments and business activities in conjunction with its third quarter financial results.

Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live audio webcast and an archive of the recording will be available here and through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the start of the call.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Investor Contact:
Jeff Warren
LifeSci Advisors
jwarren@lifesciadvisors.com
investor-relations@inspiremd.com

KALISPELL, Mont., Nov. 11, 2026 (GLOBE NEWSWIRE) — Glacier Bancorp, Inc.’s (NYSE: GBCI) Board of Directors, at a meeting held on November 11, 2026, declared a quarterly dividend of $0.35 per share. The Company has declared 167 consecutive quarterly dividends and has increased the dividend 50 times. The dividend is payable on December 17, 2026, to owners of record on December 8, 2026.

Going forward, Glacier’s Board expects to consider and declare its regular quarterly dividends in January, April, July and October of each year, beginning in January 2027, in order to coincide with the release of Glacier’s quarterly financial results.

About Glacier Bancorp, Inc.
Glacier Bancorp, Inc. is the parent company for Glacier Bank and its bank divisions: Altabank (American Fork, UT), Bank of the San Juans (Durango, CO), Citizens Community Bank (Pocatello, ID), Collegiate Peaks Bank (Buena Vista, CO), First Bank of Montana (Lewistown, MT), First Bank of Wyoming (Powell, WY), First Community Bank Utah (Layton, UT), First Security Bank (Bozeman, MT), First Security Bank of Missoula (Missoula, MT), First State Bank (Wheatland, WY), Glacier Bank (Kalispell, MT), Guaranty Bank & Trust (Mount Pleasant, TX), Heritage Bank of Nevada (Reno, NV), Mountain West Bank (Coeur d’Alene, ID), The Foothills Bank (Yuma, AZ), Valley Bank (Helena, MT), Western Security Bank (Billings, MT), and Wheatland Bank (Spokane, WA).

Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “estimate,” “anticipate,” “expect,” “will,” and similar references to future periods. Such statements are based on management’s current expectations about the Company’s business. These statements are not guarantees of future performance and involve various risks, uncertainties and assumptions that are difficult to predict. Actual results could vary materially from those contained in forward-looking statements due to many factors, including, without limitation, market and other conditions and other factors described in Glacier’s filings with the Securities and Exchange Commission (the “SEC”) from time to time. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current expectations and beliefs. The Company undertakes no obligation to publicly revise or update forward-looking statements. For more information, see the risk factors described in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC.

Contact: Randall M. Chesler, CEO
(406) 751-4722
Ron J. Copher, CFO
(406) 751-7706

HAMILTON, Bermuda, Nov. 11, 2026 (GLOBE NEWSWIRE) — Teekay Corporation Ltd. (Teekay or the Company) (NYSE:TK) today reported an update for the three months ended September 30, 2026. The update and Teekay Group’s earnings presentation are available on the Company’s website here.

About Teekay

Teekay is a leading provider of international crude oil marine transportation and marine services. Teekay provides these services through its controlling ownership interest in Teekay Tankers, a leading owner and operator of mid-sized crude tankers. Teekay Tankers has a fleet of 38 double-hulled crude oil and product tankers (which includes newbuildings) and has three time chartered-in tankers. In addition, Teekay Tankers manages and operates vessels for the Australian government and Australian energy companies as part of the marine services provided by Teekay Tankers and owns a ship-to-ship transfer business that performs full-service lightering and lightering support operations in the U.S. Gulf and Caribbean.

Teekay’s common stock is listed on the New York Stock Exchange where it trades under the symbol “TK”.

For Investor Relations enquiries contact:

E-mail: investor.relations@teekay.com
Website: www.teekay.com

NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) — Datadog, Inc. (NASDAQ:DDOG), the leading AI-powered observability and security platform, today announced that management will present at the following investor conferences:

  • The RBC Global TIMT Conference. The presentation is scheduled for Wednesday, November 18, 2026, at 10:40 a.m. ET.
  • The UBS Global Technology and AI Conference. The presentation is scheduled for Tuesday, December 1, 2026, at 12:15 p.m. ET / 10:15 a.m. MT.
  • The Barclays Global Technology Conference. The presentation is scheduled for Wednesday, December 9, 2026, at 11:45 a.m. ET / 8:45 a.m. PT.

The presentations will be webcast live, and replays of each presentation will be available for a limited time under the “Events and Presentations” section of the Company’s investor relations website at https://investors.datadoghq.com/.

About Datadog

Datadog is the leading observability and security platform for the AI era, providing businesses with unified visibility across the technology stack to manage complexity at scale. It brings applications, infrastructure, data, models, and security into one place, using AI to detect and resolve issues before they impact customers. Trusted globally by Fortune 500 companies and high-growth AI leaders, Datadog enables businesses to move faster with clarity and confidence.

Contact Information

AJ Ljubich
Datadog Investor Relations
IR@datadoghq.com

Sabrina Morse
Datadog Public Relations
Press@datadoghq.com

Event to Offer Prospective and Existing Patients Access to AirSculpt Surgeons, Personalized Consultations and Educational Programming Across 31 Centers and Virtually

TAMPA, Fla., Nov. 11, 2026 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced its first-ever nationwide Open House event, “The Gift of Body Confidence,” taking place Thursday, November 12, 2026, across its 31 centers and virtually.

The event will bring together prospective and existing patients, AirSculpt surgeons and industry partners for personalized consultations, educational discussions and interactive Q&A sessions. Attendees will learn about AirSculpt’s minimally invasive body contouring procedures, including how they differ from traditional liposuction, and solutions designed to complement weight loss journeys through targeted fat removal, skin tightening and volume enhancement. The event will also feature firsthand patient experiences, special gifts and participation from corporate partners and co-sponsors, including PatientFi®, alloClae™, Cenegenics® and Renuvion®, alongside local businesses. AirSculpt will also offer consumers some of its best packages and promotions of the season.

“Our first-ever nationwide Open House is an exciting opportunity to connect with patients and introduce them to the full range of body contouring solutions AirSculpt offers,” said Yogi Jashnani, Chief Executive Officer of AirSculpt. “As we expand our offerings to address evolving patient needs, particularly those related to weight loss, we are increasing our focus on local marketing initiatives to engage new and existing patients and build stronger connections within the communities we serve and ultimately drive incremental procedure volume.”

For additional information about “The Gift of Body Confidence” and to register for the in-person or virtual event, visit https://airsculpt.com/gift-event/.

About AirSculpt

AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

Investor Contact:

Allison Malkin
Partner, ICR Inc.
AirSculpt@icrinc.com 

Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH

PMA supplement for second-generation LungFit PH system remains under FDA review; transport capability expected to drive greater market penetration, pending approval

Reaffirms revenue guidance of $8 million for CY2026 and $16–$18 million for CY2027

Conference call today at 4:30 p.m. ET

GARDEN CITY, N.Y., Nov. 11, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced financial results for the quarter ended September 30, 2026, and provided a corporate update.

“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval,” said Robert Goodman, Chief Executive Officer of Beyond Air. “Our US pipeline is now experiencing unprecedented expansion with an acceleration in demand for our first-generation system and high receptivity to our technology and its operational efficiencies, creating a natural demand for our next generation product. We are especially pleased with the pace of new account wins and rate of renewals, which speak to the high level of customer satisfaction with our unique technology – all of which we believe we can leverage into the potential future launch of our second-generation LungFit PH system. Subject to FDA approval, the system is designed to provide a smaller footprint, reduced weight, simplified operation, longer service intervals and expanded operational flexibility. The PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground.”

Mr. Goodman continued, “We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system. We expect to complete our audit-readiness process in mid-December, and subject to FDA inspections and final approval thereafter.”

Recent Financial and Operating Highlights

  • Reported revenue of $2.3 million for the quarter ended September 30, 2026, the highest quarterly revenue in the Company’s history, representing approximately 28% growth over the same period last year and 31% growth compared with the quarter ended June 30, 2026.
  • Executed the Company’s enhanced commercial strategy for first-generation LungFit PH, supporting increased adoption of its cylinder-free nitric oxide technology.
  • Advanced preparations for the potential U.S. commercial launch of the second-generation LungFit PH system, subject to FDA approval. If approved, the Company believes the addition of transport capability would enable Beyond Air to serve as a single-source nitric oxide provider for hospitals and health systems.
  • Received FDA Breakthrough Device Designation for LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). The Company does not plan to allocate resources to further development of LungFit GO until the commercial launch of second-generation LungFit PH is well established, following FDA approval.
  • Announced a definitive agreement under which UNIVO Pharmaceutical Industries Ltd. would acquire the Company’s controlling interest in NeuroNOS Israel Ltd. The transaction is intended to provide NeuroNOS with dedicated resources, funding and strategic focus to advance its development programs.
  • Evaluating potential development partnerships and other strategic arrangements to support the continued advancement of Beyond Cancer’s pipeline, while maintaining Beyond Air’s focus and resource allocation on its commercialization of LungFit PH.

Pending Regulatory Milestones

  • The PMA supplement for the second-generation LungFit PH system, submitted in June 2025, remains under FDA review.

Financial Results for the Quarter Ended September 30, 2026

Revenue for the quarter ended September 30, 2026 was $2.3 million, compared with $1.8 million for the same period last year.

Research and development expenses for the three months ended September 30, 2026 were $1.6 million as compared to $2.5 million for the three months ended September 30, 2025. The decrease was primarily attributed to lower costs related to the second-generation LungFit PH as the majority of development is complete.

Selling, general and administrative expenses for the three months ended September 30, 2026 were $4.6 million as compared to $4.9 million for the three months ended September 30, 2025. The decrease was attributed primarily to decreases in stock-based compensation costs, partially offset by increased salaries in our sales organization as we build out our commercial team.

Other expense for the three months ended September 30, 2026 was $2.2 million as compared to other expense of $0.6 million for the three months ended September 30, 2025. The increase in expense was attributed primarily to an increase in the Company’s outstanding debt and related interest expense, in addition to a charge for scrapped materials.

Net loss attributed to common stockholders of Beyond Air, Inc. for the three months ended September 30, 2026 was $7.8 million, or a loss of $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or a loss of $24.98 per basic and diluted share, for the three months ended September 30, 2025.

As of September 30, 2026, the Company reported cash, cash equivalents, restricted cash and marketable securities of $18.5 million, including $2.7 million of cash held by NeuroNos which is included within current assets held for sale on the balance sheet and $0.7 million of cash held by Beyond Cancer. Restricted cash at September 30, 2026 was $4.8 million.

Financial Guidance

The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation LungFit PH system. The Company also reaffirms its revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval.

Conference Call and Webcast

Wednesday, November 11, 2026 at 4:30 p.m. ET

Domestic: 1-877-407-0784

International: 1-201-689-8560

Conference ID: 13763626

Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call.

As previously announced, and formally approved by the Board of Directors, the Company is transitioning its fiscal year end from March 31 to December 31, effective December 31, 2026. As a result, the Company expects to report financial results for the nine-month transition period ending December 31, 2026 on a Form 10-K/T.

About Beyond Air

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.

About LungFit

Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.

LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.

About Nitric Oxide

Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s revenue guidance for calendar year 2026 and 2027; demand for, and hospital adoption of, the Company’s LungFit PH systems, including the Company’s pipeline, new account wins and renewals; the FDA’s review of the Company’s PMA supplement for the second-generation LungFit PH system, including the expected timing of completion of the Company’s audit-readiness process and FDA inspections, and the potential approval, intended use, transport capability, commercial launch and commercial benefits of that system; the proposed NeuroNOS transaction, its consideration, closing conditions and anticipated benefits; development plans and resource allocation for LungFit GO; potential partnerships or other strategic arrangements for Beyond Cancer; the Company’s liquidity, financing needs and ability to continue as a going concern; the Company’s ability to scale its infrastructure; and the Company’s fiscal year-end transition and expected filing of a transition report on Form 10-K/T. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the Company’s ability to achieve its revenue guidance, which is based on assumptions regarding demand, hospital adoption, pricing, the timing of FDA approval of the second-generation LungFit PH system and other factors that may not be realized; whether the Company completes its audit-readiness process as anticipated; the timing and outcome of FDA inspections and whether the FDA approves the Company’s PMA supplement for the second-generation LungFit PH system, including the requested transport labeling, which may not occur in a timely manner or at all; delays in the commercial launch of the second-generation LungFit PH system; the Company’s reliance on third-party contract manufacturers; market acceptance of the Company’s products and competition in the nitric oxide market; the possibility that the contemplated investment or other conditions to the NeuroNOS transaction are not satisfied, that the transaction does not close or its anticipated benefits are not realized, or that the value of the UNIVO securities is limited; the availability of resources for LungFit GO, the outcome of further clinical development and regulatory review; the Company’s ability to secure and complete strategic arrangements for Beyond Cancer; the Company’s history of losses and substantial doubt about its ability to continue as a going concern; the Company’s ability to obtain the financing necessary to fund its operations and to satisfy its debt obligations as they come due, and the dilution that any equity financing may cause; the Company’s ability to maintain the listing of its common stock on The Nasdaq Stock Market; and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made and, except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

BEYOND AIR, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
 
    September 30, 2026     March 31, 2026  
    (Unaudited)        
ASSETS                
Current assets                
Cash and cash equivalents   $ 5,397     $ 6,740  
Marketable securities     5,652       4,901  
Restricted cash     4,832       5,622  
Accounts receivable, net     1,450       1,086  
Inventory, net     1,190       1,406  
Other current assets and prepaid expenses     5,083       5,012  
Current assets held for sale     3,024       –  
Total current assets     26,628       24,767  
                 
Licensed right to use technology     915       1,018  
Right-of-use lease assets     1,003       1,193  
Property and equipment, net     7,632       8,249  
Other assets     77       158  
TOTAL ASSETS   $ 36,255     $ 35,385  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current liabilities                
Accounts payable   $ 2,128     $ 2,417  
Accrued expenses and other current liabilities     4,094       3,372  
Operating lease liability, current portion     211       321  
Loans payable, current portion     58       401  
Current liabilities held for sale     759       –  
Total current liabilities     7,250       6,511  
                 
Operating lease liability, net     899       1,023  
Long-term debt, net     21,982       21,639  
Warrant liability     –       2  
Total liabilities     30,131       29,175  
                 
Stockholders’ equity                
Preferred Stock     –       –  
Common Stock     –       –  
Treasury stock     (25 )     (25 )
Additional paid-in capital     340,604       325,588  
Accumulated deficit     (335,324 )     (319,571 )
Accumulated other comprehensive income     72       134  
Total stockholders’ equity attributable to Beyond Air, Inc.     5,327       6,126  
Non-controlling interest     797       84  
Total stockholders’ equity     6,124       6,210  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 36,255     $ 35,385  
 

BEYOND AIR, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
(UNAUDITED)
 
    For the Three Months Ended     For the Six Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
                         
Revenues   $ 2,324     $ 1,818     $ 4,092     $ 3,578  
                                 
Cost of revenues     2,127       2,116       3,670       3,720  
                                 
Gross profit (loss)     197       (298 )     422       (142 )
                                 
Operating expenses:                                
                                 
Research and development     1,581       2,450       3,540       5,536  
Selling, general, and administrative     4,591       4,913       9,469       9,600  
Total operating expenses     6,172       7,363       13,009       15,136  
                                 
Loss from operations     (5,975 )     (7,661 )     (12,587 )     (15,278 )
                                 
Other income/(expense):                                
Dividend/investment income     93       59       196       87  
Interest and finance expense     (1,504 )     (639 )     (2,996 )     (1,187 )
Change in fair value of warrant liability     1       (1 )     2       16  
Foreign exchange gain/(loss)     29       (18 )     69       (59 )
Loss on extinguishment of debt     (252 )     –       (405 )     –  
Loss on disposal of fixed assets     –       (46 )     (52 )     (57 )
Loss on contract manufacturer’s inventory obsolescence     (567 )     –       (567 )     –  
Other income     –       48       11       142  
Total other expense     (2,200 )     (597 )     (3,742 )     (1,058 )
                                 
Loss before income taxes     (8,175 )     (8,258 )     (16,329 )     (16,336 )
                                 
Provision for income taxes     –       –       –       –  
                                 
Net loss   $ (8,175 )   $ (8,258 )   $ (16,329 )   $ (16,336 )
                                 
Less: net loss attributable to non-controlling interest     (357 )     (318 )     (576 )     (705 )
                                 
Net loss attributable to Beyond Air, Inc.   $ (7,818 )   $ (7,940 )   $ (15,753 )   $ (15,631 )
                                 
Other comprehensive income/(loss), net of tax                                
Foreign currency translation adjustment     (41 )     18       (62 )     145  
                                 
Comprehensive loss attributable to Beyond Air, Inc.   $ (7,859 )   $ (7,922 )   $ (15,815 )   $ (15,486 )
                                 
Net basic and diluted loss per share attributable to Beyond Air, Inc. (1)   $ (3.76 )   $ (24.98 )   $ (11.22 )   $ (54.95 )
                                 
Weighted average number of shares of common stock outstanding, basic and diluted (1)     2,078,853       317,829       1,403,780       284,471  

  Prior period results have been adjusted to reflect the one-for-twenty reverse stock split in July 2026

  • Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatoprost Drug Pad-IOL System (BIM-IOL System) and accelerating premium IOL portfolio expansion capability.
  • Announced groundbreaking four-year first-in-human (FIH) efficacy and safety follow-up data of the BIM-IOL System, with a 37% reduction in mean intraocular pressure (IOP) across all dose levels and 86% of patients remaining off all topical IOP-lowering drops.
  • Enrollment remains on track in the registrational Phase 3 trials of the BIM-IOL System, with completion expected in 2027.
  • Announces completion of first implantations in the FIH study of the Bimatoprost-Drug Ring System (BIM-DRS), a non-IOL-based sustained drug delivery system for glaucoma designed to deliver up to seven years of bimatoprost.
  • Cash, cash equivalents and short-term investments of $215.8 million on September 30, 2026, are expected to fund planned operations through 2028.

IRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the third quarter ended September 30, 2026.

“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability. In parallel, enrollment in our Phase 3 trials of the BIM-IOL System remains on track, and we have secured long-term commercial manufacturing supply of the IOL for the BIM-IOL System and have become a supplier of other world-class IOLs,” stated Patrick Mooney, chief executive officer of SpyGlass Pharma. “We are pleased to announce that our BIM-DRS is now in the clinic, with successful implantations of the next-generation drug delivery system in glaucoma patients who have had prior cataract surgery.”

Corporate Highlights

Acquisition of Advanced Vision Science, Inc. In October, SpyGlass Pharma acquired all the outstanding shares of common stock of AVS, an ophthalmic medical device company and manufacturer of IOLs and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd. and is the current supplier of SpyGlass Pharma’s IOL in its two Phase 3 registrational trials evaluating the BIM-IOL System.

Announced Four-Year BIM-IOL FIH Efficacy and Safety Follow-Up Data. In October, SpyGlass Pharma announced groundbreaking four-year follow-up data of its FIH study of the BIM-IOL System, which demonstrated that 86% of patients were free from using topical IOP-lowering drops and showed a 37% reduction in mean IOP across all doses. Additionally, 90% of patients maintained ≥20/25 best corrected distance visual acuity (BCDVA). SpyGlass Pharma designed the BIM-IOL System in the FIH trial to deliver bimatoprost for up to seven years. No product-related adverse events were reported to date.

Presentation of Detailed Phase 1/2 Data from the BIM-IOL System Clinical Program at the American Academy of Ophthalmology (AAO) Annual Meeting. In October, Jeffrey Kammer, M.D., associate professor of ophthalmology at Vanderbilt University, presented topline 12-month Phase 1/2 data at AAO in New Orleans. The detailed 12-month safety and efficacy results reinforced the sustained IOP reduction at that timepoint, and the elimination of topical eye drops for 98% of patients who received the intended commercial dose of the BIM-IOL System. Additionally, the BIM-IOL System demonstrated improved visual performance, with mean BCDVA of 86 letters, which is equivalent to 20/20 vision. Lastly, Dr. Kammer presented new data showing endothelial cell count loss following BIM-IOL System implantation was consistent with routine cataract surgery.

Completed First Implantations of the BIM-DRS in FIH Trial. In October, SpyGlass Pharma successfully completed first implantations of its next-generation drug delivery platform in the FIH trial of the BIM-DRS. BIM-DRS is a non-IOL-based system that is implanted in the ciliary sulcus and available to all ophthalmic surgeons, designed to deliver bimatoprost for up to seven years with removal and replacement capability to deliver lifetime IOP control without the burden of daily eye drops. Importantly, BIM-DRS represents the expansion of SpyGlass Pharma’s drug delivery technology beyond traditional cataract surgery and has the potential to provide continuous care over the lifetime of a patient. SpyGlass Pharma anticipates providing preliminary safety and IOP-lowering efficacy data for the BIM-DRS FIH trial in 2027.

Third Quarter 2026 Financial Results

Cash, Cash Equivalents and Short-Term Investments totaled $215.8 million as of September 30, 2026.

Research and Development Expenses were $10.0 million for the third quarter of 2026, compared to $8.1 million for the third quarter of 2025. The increase was primarily due to the hiring of clinical personnel and continued enrollment in the Phase 3 registrational trials for the BIM-IOL System.

General and Administrative Expenses were $16.2 million for the third quarter of 2026, compared to $3.0 million for the third quarter of 2025. The increase was primarily due to higher professional service fees and personnel costs.

Net Loss was $24.3 million, or ($0.73) per basic and diluted share, for the third quarter of 2026, compared to $9.8 million, or ($4.53) per basic and diluted share, for the same period of 2025.

About the Bimatoprost Drug Pad-IOL System

SpyGlass Pharma’s lead product candidate, the BIM-IOL System, comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated IOP in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). The BIM-IOL System being evaluated in ongoing Phase 3 clinical trials is designed to consistently deliver three years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT.

SpyGlass Pharma continues long-term follow-up of patients in both the FIH trial and Phase 1/2 trial as well as patient enrollment in ongoing Phase 3 clinical trials. SpyGlass Pharma plans to work with the FDA to advance the program through 505(b)(2) New Drug Application (NDA) submission and ultimately to potential commercial approval.

About the Bimatoprost-Drug Ring System

BIM-DRS is a novel, non-bioerodible, non-IOL-based, sustained-release implant, designed to consistently deliver up to seven years of bimatoprost. BIM-DRS is implanted in a standalone procedure in the ciliary sulcus space, offering extended care for pseudophakic eyes with OAG or OHT and enabling retreatment of patients who have previously received the BIM-IOL System. BIM-DRS is engineered to be a removable and replaceable system, potentially allowing for continuous care over a patient’s lifetime.

About SpyGlass Pharma

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.

The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.

The Company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The terms “lasting,” “long-term,” and “enduring” refer to being able to control IOP for years with one procedure compared to current eye drops, which require dosing daily or even more frequently. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding: the potential benefits and impact of SpyGlass Pharma’s portfolio on patients, including the potential to provide lasting IOP reduction, anticipated presentation of additional data, SpyGlass Pharma’s plans relating to the Phase 3 clinical development of the BIM-IOL System toward enrollment completion and clinical development of BIM-DRS, the anticipated benefits of SpyGlass Pharma’s acquisition of AVS; and the potential commercial launch and market adoption of the BIM-IOL System after FDA approval. The forward-looking statements contained herein are based upon SpyGlass Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in the Risk Factors section of the Company’s Quarterly Report on Form 10-Q for the three and nine month period ended September 30, 2026 expected to be filed with the Securities and Exchange Commission on November 12, 2026, and in similar disclosures set forth in the other documents that SpyGlass Pharma has filed and may file from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and SpyGlass Pharma assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. SpyGlass Pharma’s views in these forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Media Contact:
Nami Surendranath
+1 (402) 507-6757
nami.surendranath@omc.com

Investor Contact:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
investors@spyglasspharma.com

SpyGlass Pharma, Inc.
Condensed Balance Sheets
(in thousands, except share and per share data)
(unaudited)
 
  Three Months Ended September 30,   Nine Months Ended September 30,
  2026   2025   2026   2025
Operating expenses                      
Research and development $ 10,034     $ 8,093     $ 29,518     $ 21,478  
General and administrative 16,211     3,008     34,103     6,343  
Total operating expenses 26,245     11,101     63,621     27,821  
Loss from operations (26,245 )   (11,101 )   (63,621 )   (27,821 )
Other income                      
Interest income 1,992     1,285     5,686     2,033  
Change in fair value of redeemable convertible preferred stock tranche liability –     –     –     (1,526 )
Total other income 1,992     1,285     5,686     507  
Loss before income tax (24,253 )   (9,816 )   (57,935 )   (27,314 )
Income tax provision –     –     –     –  
Net loss and comprehensive loss $ (24,253 )   $ (9,816 )   $ (57,935 )   $ (27,314 )
Net loss per share                      
Weighted average common stock outstanding, basic and diluted 33,451,025     2,166,976     28,989,007     2,224,482  
Net loss per share, basic and diluted $ (0.73 )   $ (4.53 )   $ (2.00 )   $ (12.28 )
 

SpyGlass Pharma, Inc.
Condensed Statements of Operations
(in thousands, except share and per share data)
(unaudited)
 
  September 30, 2026   December 31, 2025
Assets          
Current assets          
Cash and cash equivalents $                    208,687     $                      96,358  
Short-term investments 7,072     11,078  
Other receivables 574     431  
Prepaid expenses and other current assets 1,582     901  
Total current assets 217,915     108,768  
Other non-current assets 689     492  
Property and equipment, net 6,344     2,339  
Deferred offering costs –     2,715  
Right-of-use asset 1,401     1,552  
Total assets $                    226,349     $                    115,866  
Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)          
Current liabilities          
Accounts payable $                         5,649     $                         2,696  
Payroll-related accruals 2,508     2,182  
Other current liabilities 6,140     3,706  
Total current liabilities 14,297     8,584  
Lease liability, non-current 1,609     1,582  
Total liabilities 15,906     10,166  
Commitments and contingencies          
Redeemable convertible preferred stock, $.00001 par value; 0 shares authorized, issued and outstanding as of September 30, 2026; 116,618,581 shares authorized,  20,341,968 shares issued and outstanding as of December 31, 2025 (aggregate liquidation preference of $0 and $200,878 as of September 30, 2026 and December 31, 2025, respectively) –     204,537  
Stockholders’ equity (deficit)          
Preferred stock, $.00001 par value; 200,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2026; 0 shares authorized, issued, and outstanding as of December 31, 2025 –     –  
Common stock, $.00001 par value; 1,000,000,000 shares authorized, 33,457,450  shares issued and outstanding as of September 30, 2026;  154,383,336 shares authorized; 2,203,620 shares issued and outstanding as of December 31, 2025 –     –  
Common stock additional paid-in capital 373,108     5,893  
Accumulated deficit (162,665 )   (104,730 )
Total stockholders’ equity (deficit) 210,443     (98,837 )
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) $                    226,349     $                    115,866  

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.